Published in Nephrol Dial Transplant on September 23, 2006
Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) (2010) 2.94
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician (2013) 1.67
Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol (2010) 1.22
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Impact of treating the metabolic syndrome on chronic kidney disease. Nat Rev Nephrol (2009) 0.96
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol (2014) 0.87
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol (2015) 0.87
Simvastatin protects bladder and renal functions following spinal cord injury in rats. J Inflamm (Lond) (2010) 0.86
Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res (2011) 0.85
Association of serum uric acid and coronary artery disease in premenopausal women. PLoS One (2014) 0.85
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J (2007) 0.82
Statins and renovascular disease in the elderly: a population-based cohort study. Eur Heart J (2010) 0.82
A novel therapeutic effect of statins on nephrogenic diabetes insipidus. J Cell Mol Med (2015) 0.81
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front Biosci (Landmark Ed) (2009) 0.81
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol (2015) 0.81
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol (2008) 0.81
Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. Cardiol Res Pract (2011) 0.80
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clin Exp Nephrol (2012) 0.79
Do statins play a role in renoprotection? Clin Exp Nephrol (2014) 0.79
Kidney function and estimated vascular risk in patients with primary dyslipidemia. Open Cardiovasc Med J (2009) 0.79
Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Lipids Health Dis (2016) 0.77
Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role? Open Cardiovasc Med J (2011) 0.77
Renoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3. PLoS One (2016) 0.77
Association between serum uric acid levels and cardiovascular risk among university workers from the State of Mexico: a nested case-control study. BMC Public Health (2013) 0.77
A cross-sectional analysis of the relationship between uric acid and coronary atherosclerosis in patients with suspected coronary artery disease in China. BMC Cardiovasc Disord (2014) 0.76
Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. Oman Med J (2012) 0.75
Almond supplementation reduces serum uric acid in coronary artery disease patients: a randomized controlled trial. Nutr J (2016) 0.75
Attainment of multifactorial treatment targets among the elderly in a lipid clinic. J Geriatr Cardiol (2015) 0.75
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clin Exp Nephrol (2016) 0.75
Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. Nutrients (2017) 0.75
High serum uric acid levels may increase mortality and major adverse cardiovascular events in patients with acute myocardial infarction. Saudi Med J (2017) 0.75
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin (2002) 3.12
A review of drug-induced hyponatremia. Am J Kidney Dis (2008) 2.97
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant (2006) 1.90
Time for new indications for statins? Med Sci Monit (2009) 1.87
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care (2002) 1.73
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth? Eur J Intern Med (2010) 1.67
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med (2002) 1.49
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord (2012) 1.44
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Ann Hematol (2004) 1.39
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors? Ann Allergy Asthma Immunol (2007) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.27
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Apolipoprotein E and renal disease. Am J Kidney Dis (2004) 1.20
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Epidemiological survey for the prevalence of overweight and abdominal obesity in Greek adolescents. Obesity (Silver Spring) (2008) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid (2007) 1.12
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09